Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

icahn-school-of-medicine

Icahn School Of Medicine, News on Icahn School Of Medicine, stories on Icahn School Of Medicine, articles on Icahn School Of Medicine, Icahn School Of Medicine stories at Wion, Icahn School Of Medicine news, Icahn School Of Medicine latest news

icahn school-of-medicine

Lancet opens probe into ‘unreliable’ anti-stroke medicine